F002 Critical Gaps and Controversies in Laser Treatment of Port Wine Birthmarks and other Vascular Anomalies
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
1. Define the genetics of vascular anomalies including PWB with an update on molecular drivers for disease progression
2. Review the utility of non-invasive imaging for vascular anomalies including PWB
3. Describe the optimal timing for laser treatment initiation for vascular anomalies, including the international need for care, and innovative laser approaches to improve treatment responses
4. Elucidate evidence-based approaches for diagnosis and treatment of complicated infantile hemangiomas, including the role of laser
5. In a "case-based" format, review a variety of approaches to multi-disciplinary treatments including laser for a variety of vascular anomalies including microcystic lymphatic malformations, venous malformations, and glomulovenous malformations
LEARNING OBJECTIVES
Define the genetics of vascular anomalies including port wine birthmarks, and discuss opportunities for targeted therapy and non-invasive imaging to refine laser parameters.
Review the optimal timing for laser initiation for port wine birthmarks.
Review innovative approaches to laser treatment for vascular anomalies including port wine birthmarks, microcystic lymphatic malformations, venous malformations, and glomulovenous malformations in a "case based" format.
SCHEDULE
5:00 PM
Define the genetics of vascular anomalies including PWB with an update on molecular drivers for disease progression
Lisa Arkin, MD, FAAD
5:20 PM
Review the utility of non-invasive imaging for vascular anomalies including PWB
Kristen Marie Kelly, MD, FAAD
5:40 PM
Describe the optimal timing for laser treatment initiation for PWB and other vascular anomalies, and innovative laser approaches to improve treatment responses
Yakir S Levin, MD, PhD, FAAD
6:00 PM
Elucidate evidence-based approaches for diagnosis and treatment of complicated infantile hemangiomas, including the role of laser
Denise W Metry, MD, FAAD
6:20 PM
11. Review the international need for treatment and innovative approaches to close this gap in care and access
Anh Quynh Ngoc Phan, Thanh-Nga Trinh Tran, MD, PhD, FAAD
6:40 PM
In a "case-based" format, review a variety of approaches to multi-disciplinary treatments including laser for complicated vascular anomalies
SPEAKERS
Lisa Arkin, MD, FAAD
Kristen Marie Kelly, MD, FAAD
Yakir S Levin, MD, PhD, FAAD
Denise W Metry, MD, FAAD
Anh Quynh Ngoc Phan
Thanh-Nga Trinh Tran, MD, PhD, FAAD
SPEAKER DISCLOSURES
Lisa Arkin, MD, FAAD
Amgen – Investigator(Grants/Research Funding); Eli Lilly – Investigator(Grants/Research Funding); Merck – Consultant (1099 relationship)(Fees); Regeneron – Consultant(Honoraria); Sanofi – Speaker/Faculty Education(Honoraria);
Kristen Marie Kelly, MD, FAAD
Asclepion Laser Technologies GmbH – Other(Equipment); BioPhotas Inc. – Investigator(Grants/Research Funding); Candela Corporation – Other(Equipment), Other(No Compensation Received); IQVIA – Consultant(Honoraria); Lutronic – Investigator(Equipment), Investigator(Grants/Research Funding); NobelPharma – Consultant (1099 relationship)(Honoraria); Orlucent – Investigator(Grants/Research Funding); Primus Pharmaceuticals – Advisory Board(Honoraria), Consultant (1099 relationship)(Fees); R2 Dermatology, Inc. – Investigator(Equipment); Reliant Technologies, Inc. – Other(Equipment); Sciton, Inc. – Consultant(Honoraria), Speaker(Honoraria); Shanghai Fudan-Zhangjiang Bio Pharmaceutical Co., Ltd. – Consultant(Honoraria), Investigator(Grants/Research Funding); Thermage – Other(Equipment); Vivosight – Consultant (1099 relationship)(Equipment), Consultant (1099 relationship)(Grants/Research Funding);
Yakir S Levin, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Denise W Metry, MD, FAAD
No financial relationships exist with ineligible companies.
Anh Quynh Ngoc Phan
No financial relationships exist with ineligible companies.
Thanh-Nga Trinh Tran, MD, PhD, FAAD
Amgen – Consultant (1099 relationship)(Honoraria); Arcutis Biotherapeutics – Advisory Board(Honoraria); AVAVA, LLC – Consultant(Honoraria); Bristol-Myers Squibb – Advisory Board(Honoraria);